Glycolytic enzyme, PGK1, plays a crucial role in malignant meningioma.

2021 Fiscal Year Final Research Report

• Project/Area Number: 19K09501
• Research Category: Grant-in-Aid for Scientific Research (C)
• Allocation Type: Multi-year Fund
• Section: 一般
• Review Section: Basic Section 56010:Neurosurgery-related
• Research Institution: Tokyo Medical and Dental University
• Principal Investigator: Kudo Takumi 東京医科歯科大学, 大学院医歯学総合研究科, 非常勤講師 (90632125)
• Project Period (FY): 2019-04-01 – 2022-03-31
• Keywords: 悪性髄膜種 / 解糖系酵素 / PGK1

Outline of Final Research Achievements

BACKGROUND: Some meningioma is classified as WHO grade II or grade III. Our previous study showed Phosphoglycerate Kinase 1 (PGK1), one of glycolytic enzyme was identified as an oncogene of malignant meningioma. In this study we investigated the role of PGK1 in malignant meningioma. METHOD: PGK1 were transduced or suppressed in malignant meningioma cell line, HKBMM, then the phenotype was analyzed. RESULTs: The proliferation of PGK1-suppressed HKBMM cells was significantly suppressed in hypoxic condition. PGK1-overexpressed HKBMM cells showed an increase of colony formation in hypoxic condition. Metabolome analysis using PGK1-suppressed HKBMM cells which were incubated in hypoxic condition showed that the expression of downstream component of PGK1 in the glycolysis.
CONCLUSION: These results suggested that PGK1 functions as a tumorigenic molecule in malignant meningioma. Translational researches were required to confirm the newly identified therapeutic target.

Free Research Field

脳神経外科

Academic Significance and Societal Importance of the Research Achievements

髄膜腫は原発性頭蓋内腫瘍のうち最も発生頻度の高い腫瘍の一つであり、悪性髄膜腫は再発率が高く、生存予後も満足のいくものではない。本研究により悪性髄膜腫に解糖系が関与しており、PGK1は悪性髄膜腫の治療標的になりうることが示唆された。今後PGK1や解糖系酵素を標的とした治療方法を確立することで悪性髄膜腫の予後の改善が期待される。